Drugs / Adult stem cells
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00113243 | Dec 2004 → Dec 2007 | peripheral vascular disease | Murphy, Michael P., MD | Unknown | No outcome recorded |
| Phase 22 trials · 2 missed | ||||||
| Phase 2 | NCT00824005 | Mar 2009 → Nov 2011 | cardiomyopathy, left ventricular failure, myocardial ischemia | The University of Texas Health Science Center, Houston | Completed | Missed primary |
| Phase 2 | NCT00684060 | Jul 2008 → Aug 2011 | left ventricular failure | The University of Texas Health Science Center, Houston | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00684021 Comparator | Jul 2008 → May 2012 | left ventricular failure | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adult stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00824005 ↗ |
| Modality | Cell therapy | “This study will evaluate the safety and effectiveness of using adult stem cell infusions 2 to 3 weeks after a heart attack” NCT00684060 ↗ |
| Route | Intramuscular | “the stem cells will then be removed and injected directly into the muscle of the diseased leg” NCT00113243 ↗ |